Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment.

Edwards, Khary; Uruska, Aleksandra; Duda-Sobczak, Anna; Zozulinska-Ziolkiewicz, Dorota; Lingvay, Ildiko

Edwards, Khary; Uruska, Aleksandra; Duda-Sobczak, Anna; Zozulinska-Ziolkiewicz, Dorota; Lingvay, Ildiko.

Afiliación

Edwards K; Department of Internal Medicine/Endocrinology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8857, USA.
Uruska A; Department of Internal Medicine and Diabetology, Poznan University of Medical Sciences, Poznan, Poland.
Duda-Sobczak A; Department of Internal Medicine and Diabetology, Poznan University of Medical Sciences, Poznan, Poland.
Zozulinska-Ziolkiewicz D; Department of Internal Medicine and Diabetology, Poznan University of Medical Sciences, Poznan, Poland.
Lingvay I; Department of Internal Medicine/Endocrinology, Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Ther Adv Endocrinol Metab ; 14: 20420188231180987, 2023.

Article en En | MEDLINE | ID: mdl-37440840

Palabras clave

GLP-1RA; SGLT2i; T1DM; patient-reported outcomes

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Qualitative_research / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Ther Adv Endocrinol Metab Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google